Infectious Disease · Gastrointestinal Infections
The facts most likely to be tested
The most significant risk factor for Clostridioides difficile infection (CDI) is recent or prolonged antibiotic use, particularly clindamycin, fluoroquinolones, or cephalosporins.
The primary mechanism of pathogenesis involves the production of exotoxins A (enterotoxin) and B (cytotoxin), which cause colonic mucosal inflammation and pseudomembrane formation.
The gold standard for diagnosis is the nucleic acid amplification test (NAAT) for the toxigenic C. difficile gene, often combined with an enzyme immunoassay (EIA) for glutamate dehydrogenase (GDH) and toxins A/B.
First-line treatment for an initial episode of non-severe or severe CDI is oral fidaxomicin for 10 days.
Oral vancomycin is an acceptable alternative first-line treatment if fidaxomicin is unavailable or cost-prohibitive.
Fulminant CDI, characterized by hypotension, shock, ileus, or megacolon, requires treatment with high-dose oral vancomycin plus intravenous metronidazole.
Surgical consultation for subtotal colectomy is mandatory in patients with fulminant CDI who fail medical therapy or develop perforation.
Vignette unlocked
A 68-year-old male presents with 8 days of watery, non-bloody diarrhea and lower abdominal cramping. He was recently hospitalized for pneumonia and completed a 10-day course of levofloxacin. On physical exam, he is febrile to 101.2°F, has diffuse abdominal tenderness without guarding, and a white blood cell count of 18,000/µL. A stool study is positive for GDH antigen and toxin A/B.
What is the most appropriate first-line pharmacologic treatment for this patient?
Oral fidaxomicin
The patient presents with classic symptoms of CDI following antibiotic exposure, and current guidelines recommend fidaxomicin as the preferred first-line agent for initial episodes.
Full handout
High yield triage
Etiology / Epidemiology
Associated with recent antibiotic use (especially clindamycin, fluoroquinolones, cephalosporins) and hospitalization.
Clinical Manifestations
Presents with watery diarrhea, abdominal cramps, and leukocytosis; severe cases show pseudomembranous colitis.
Diagnosis
Gold standard is Stool NAAT (PCR) for toxin gene; GDH plus toxin EIA is common clinical screening.
Treatment
Fidaxomicin is the preferred first-line agent; avoid antimotility agents.
Prognosis
Risk of recurrence is 20-30%; severe cases may progress to toxic megacolon.
Full handout
Epidemiology & Etiology
Primarily affects patients with disrupted gut flora following broad-spectrum antibiotic exposure. Advanced age and proton pump inhibitor (PPI) use are significant independent risk factors. Transmission occurs via the fecal-oral route, often in healthcare settings.
Pertinent Anatomy
The infection primarily targets the colon, leading to mucosal inflammation. Severe inflammation can result in thinning of the colonic wall, predisposing to perforation.
Pathophysiology
Ingestion of spores leads to colonization after antibiotic-induced dysbiosis. The bacteria produce Toxin A (enterotoxin) and Toxin B (cytotoxin), which disrupt the cytoskeleton and cause epithelial cell death. This results in the formation of pseudomembranes composed of fibrin, inflammatory cells, and necrotic debris.
Clinical Manifestations
Patients typically present with profuse, foul-smelling watery diarrhea and lower abdominal pain. Physical exam may reveal tenderness and leukocytosis. Red flags include high fever, hypotension, and abdominal distension, which suggest toxic megacolon or impending perforation.
Diagnosis
The Stool NAAT (PCR) is the most sensitive diagnostic test. Clinical algorithms often use GDH antigen combined with Toxin A/B EIA for rapid detection. Endoscopy is reserved for atypical cases, revealing pathognomonic pseudomembranes.
Treatment
Fidaxomicin is the first-line treatment for initial episodes. Oral Vancomycin is an acceptable alternative if fidaxomicin is unavailable. Avoid antimotility agents (e.g., loperamide) as they increase the risk of toxic megacolon. Fulminant cases require IV Metronidazole plus high-dose oral Vancomycin.
Prognosis
Recurrence occurs in 20-30% of patients, often requiring prolonged tapers or fecal microbiota transplantation (FMT). Monitor for toxic megacolon via serial abdominal imaging if clinical status deteriorates.
Differential Diagnosis
Viral gastroenteritis: usually self-limiting and lacks pseudomembranes
IBD flare: history of chronic bloody diarrhea and systemic symptoms
Ischemic colitis: sudden onset pain out of proportion to exam in elderly
Enterotoxigenic E. coli: typically associated with travel history
Microscopic colitis: chronic watery diarrhea with normal colonoscopy appearance